Opinion|Videos|May 10, 2024
Second-Line Treatment of Patients With EGFR-Mutated NSCLC
Following a review of the MARIPOSA-2 trial, experts on non–small cell lung cancer discuss treatment approaches in the second line.
Advertisement
Episodes in this series
Advertisement
Related to this article
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
3
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
4
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
5